Internal Mammary Sentinel Lymph Node Biopsy in Early Breast Cancer Patients With Clinically Axillary Node -Negative
Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
In addition to the axillary lymph node, the internal mammary lymph node (IMLN) chain is also
the first-echelon nodal drainage site for metastasis and provides important prognostic
information in breast cancer patients. The internal mammary sentinel lymph node biopsy
(IM-SLNB) provides a less invasive method of assessing the IMLN than surgical dissection. But
the low visualization rate of IMSLN has been a restriction of IM-SLNB. This clinical trial is
carried out to improve the visualization rate of IMSLN with modified techniques: (1) The
radiotracer is injected intraparenchymally into 2~4 quadrants of breast. (2) The radiotracer
is injected in a high volume. (3) The radiotracer should be injected under ultrasonographic
guidance.